Abstract

<div>Abstract<p><b>Purpose:</b> The purpose of this study was to determine whether histone deacetylase (HDAC) inhibitors (HDACI) such as vorinostat or entinostat (SNDX-275) could increase the lethality of the dual Bcr/Abl-Aurora kinase inhibitor KW-2449 in various Bcr/Abl<sup>+</sup> human leukemia cells, including those resistant to imatinib mesylate (IM).</p><p><b>Experimental Design:</b> Bcr/Abl<sup>+</sup> chronic myelogenous leukemia (CML) and acute lymphoblastic leukemia (ALL) cells, including those resistant to IM (T315I, E255K), were exposed to KW-2449 in the presence or absence of vorinostat or SNDX-275, after which apoptosis and effects on signaling pathways were examined. <i>In vivo</i> studies combining HDACIs and KW2449 were carried out by using a systemic IM-resistant ALL xenograft model.</p><p><b>Results:</b> Coadministration of HDACIs synergistically increased KW-2449 lethality <i>in vitro</i> in multiple CML and Ph<sup>+</sup> ALL cell types including human IM resistant cells (e.g., BV-173/E255K and Adult/T315I). Combined treatment resulted in inactivation of Bcr/Abl and downstream targets (e.g., STAT5 and CRKL), as well as increased reactive oxygen species (ROS) generation and DNA damage (γH2A.X). The latter events and cell death were significantly attenuated by free radical scavengers (TBAP). Increased lethality was also observed in primary CD34<sup>+</sup> cells from patients with CML, but not in normal CD34<sup>+</sup> cells. Finally, minimally active vorinostat or SNDX275 doses markedly increased KW2449 antitumor effects and significantly prolonged the survival of murine xenografts bearing IM-resistant ALL cells (BV173/E255K).</p><p><b>Conclusions:</b> HDACIs increase KW-2449 lethality in Bcr/Abl<sup>+</sup> cells in association with inhibition of Bcr/Abl, generation of ROS, and induction of DNA damage. This strategy preferentially targets primary Bcr/Abl<sup>+</sup> hematopoietic cells and exhibits enhanced <i>in vivo</i> activity. Combining KW-2449 with HDACIs warrants attention in IM-resistant Bcr/Abl<sup>+</sup> leukemias. <i>Clin Cancer Res; 17(10); 3219–32. ©2011 AACR</i>.</p></div>

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.